A5 Laboratories Inc.
OTC Bulletin Board : AFLB

A5 Laboratories Inc.

February 01, 2011 10:30 ET

A5 Laboratories, Inc. Announces Successful Production of VI-1718 Interferon Product

MONTREAL, QUEBEC--(Marketwire - Feb. 1, 2011) - A5 Laboratories Inc. (A5 Labs) (OTCBB:AFLB) announced today the successful production of its VI-1718 interferon product by its European manufacturing partner. The European partner was successful in producing 2,000 doses of VI-1718 based on A5 Labs proprietary novel production technology. The company was further informed that the VI-1718 samples passed all quality control and anti-viral tests conducted by the European partner.

A5 Labs will receive the 2,000 doses in the next 3 to 4 weeks, at which time the company will conduct its own as well as independent lab tests for potency and efficacy.

"I am extremely pleased with the production of VI-1718 samples and the test results obtained by our European manufacturing partners. We have thus far shown that our technology is capable of producing small scale potent interferon products. In the next 3 to 4 weeks will release the complete results of the potency and efficacy of the VI-1718. " said Dr. Richard Azani, President and CEO.

More information about the Company is available at its corporate website at www.a5labs.com

About A5 Labs:

A5 Labs is a contract research based organization servicing the pharmaceutical and biotechnology companies in North America. The company utilizes its research capabilities to license and acquire novel biotechnology products for development and commercialization.

Safe Harbor Statement:

Except for historical information contained herein, the matters set forth above may be forward-looking statements that involve certain risks and uncertainties that could cause actual results to differ from those in the forward-looking statements. Words such as "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to A5 or its management, identify forward-looking statements. Such forward-looking statements are based on the current beliefs of management, as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors such as the level of business and consumer spending, the amount of sales of A5's products, the competitive environment within the industry, the ability of A5 to continue to expand its operations, the level of costs incurred in connection with A5's expansion efforts, economic conditions in the industry and the financial strength of A5's customers and suppliers. A5 does not undertake any obligation to update such forward-looking statements. Investors are also directed to consider all other risks and uncertainties.

Contact Information